A multidimensional exploration of metabolic syndrome components;Uma exploração multidimensional dos componentes da síndrome metabólica

Cadernos de Saude Publica

Volumn 25, Issue 5, 2009, Pages 1073-1082

  de Freitas, Eulilian Dias ^a   Haddad, João Paulo Amaral ^a   Velásquez Meléndez, Gustavo ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Metabolic syndrome x; Obesity; Rural population

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; BRAZIL; DYSLIPIDEMIA; EPIDEMIOLOGY; FEMALE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY; RURAL POPULATION; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAZIL; DYSLIPIDEMIAS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; RURAL POPULATION; SEX FACTORS; YOUNG ADULT;

EID: 69249202446     PISSN: 0102311X     EISSN: 16784464     Source Type: Journal    
DOI: 10.1590/s0102-311x2009000500014     Document Type: Article

References (41)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-607.
2. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Diabetologia 2005; 48:1684-99.
3. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15:539-53.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.
5. Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002; 28:364-76.
6. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9:237-52.
7. International Diabetes Federation. The IDF consensus worldwide definition of the Metabolic Syndrome. http://www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf (acessado em 15/Set/2006).
8. Heliövaara MK, Teppo AM, Karonen SL, Tuominen JA, Ebeling P. Plasma IL-6 concentration is inversely related to insulin sensitivity, and acute-phase proteins associate with glucose and lipid metabolism in health subjects. Diabetes Obes Metab 2005; 7:729-36.
9. Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 2003; 168:351-8.
10. Meigs JB, Wilson PW, Nathan DM, D'Agostinho RB, Williams K, Halner SM. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart Study and Framingham Offspring Studies. Diabetes 2003; 52:2160-7.
11. Chapidze G, Dolidze N, Enquobahrie DA, Kapanadze S, Latsabidze N, William MA. Metabolic syndrome and C-reactive protein among cardiology patients. Arch Med Res 2007; 38:783-8.
12. Moebus S, Hanisch JU, Aidelsburger P, Bramlage P, Wasem J, Jöeckel KH. Impact of 4 different definitions used for the assessment of the prevalence of the metabolic syndrome in primary healthcare: The German Metabolic and Cardiovascular Risk Project. Cardiovasc Diabetol 2007, 6:22.
13. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. JAMA 2002; 287:356-9.
14. Pinto ME, Lomelí AH, Gambá MAA, Flores HM, Mellado AV. Síndrome metabólico en adultos de 20 a 40 años en una comunidad rural mexicana. Rev Méd Inst Mex Seguro Soc 2006; 44:329-35.
15. Oliveira EP, Souza MLA, Lima MDA. Prevalência de síndrome metabólica em uma área rural do semi-árido baiano. Arq Bras Endocrinol Metabol 2006; 50:456-65.
16. Velásquez-Meléndez G, Gazzinelli A, Côrrea-Oliveira R, Pimenta AM, Kac G. Prevalence of metabolic syndrome in a rural area of Brazil. São Paulo Med J 2007; 125:155-62.
17. Snehalatha C, Sivasankari S, Satyavani K, Vijay V, Ramachandran A. Insulin resistance alone does not explain the clustering of cardiovascular risk factors in southern India. Diabet Med 2000; 17:152-7.
18. Mingoti AS. Análise de dados através de métodos de estatística multivariada: uma abordagem aplicada. Belo Horizonte: Editora da Universidade Federal de Minas Gerais; 2005.
19. Edwards KL, Austin MA, Newman B, Mayer E, Krauss RM, Selby JV. Multivariate analysis of the insulin resistance syndrome in women. Arterioscler Thromb 1994; 14:1940-5.
20. Shen BJ, Goldberg RB, Llabre MM, Schneiderman N. Is the factor structure of the metabolic syndrome comparable between men and women and the across three ethnic groups: the Miami Community Health Study. Ann Epidemiol 2006; 16:131-7.
21. Lafortuna CL, Adorni F, Agosti F, Sartorio A. Factor analysis of metabolic syndrome components in obese women. Nutr Metab Cardiovasc Dis 2008; 18:233-41.
22. Shmulewitz D, Auerbach SB, Lehner T, Blundell ML, Winick JD, Youngman LD, et al. Epidemiology and factor analysis of obesity, type II diabetes, hypertension, and dyslipidemia (syndrome X) on the island of Kosrae, Federated States of Micronesia. Hum Hered 2001; 51:8-19.
23. Lin JD, Wan HL, Li JC, Wu CZ, Kuo SW, Hsieh CH, et al. Impaired glucose tolerance and impaired fasting glucose share similar underlying pathophysiologies. Tohoku J Exp Med 2007; 212:349-57.
24. Maison P, Day NE, Byrne CD, Wareham NJ, Hales CN. Do different dimensions of the metabolic syndrome change together over time? Diabetes Care 2001; 24:1758-63.
25. Kloss H, Passos LK, Lo-Verde P, Oliveira AC, Gazzinelli A. Distribution and Schistosoma mansoni infection of Biomphalaria glabrata in different habitants in a rural area in the Jequitinhonha Valley, Minas Gerais, Brazil: environmental and epidemiological aspects. Mem Inst Oswaldo Cruz 2004; 99:673-80.
26. Lohman TG, Roche AF, Martorell R. Anthropometric standardization reference manual. Champaign: Human Kinetics; 1988.
27. World Health Organization. Obesity: preventing and managing the global epidemic. Geneva: World Health Organization; 1998. (WHO Technical Report Series, 894).
28. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157:2413-46.
29. Sociedade Brasileira de Hipertensão. IV diretrizes brasileiras de hipertensão arterial. http://www.sbh.org.br/documentos/index.asp (acessado em 09/Out/2006).
30. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003; 139:802-9.
31. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-9.
32. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109:433-8.
33. Ang LW, Ma S, Cutter J, Chew SK, Tan CE, Tai ES. The metabolic syndrome in Chine, Malays and Asians Indians: factor analysis of data from the 1998 Singapore National health survey. Diabetes Res Clin Pract 2005; 67:53-62.
34. Anderson PJ, Critchley JAJH, Chan JCN, Cockram CS, Lee ZSK, Thomas GN, et al. Factor analysis of the metabolic syndrome: obesity vs. insulin resistance as the central abnormality. Int J Obes 2001; 25:1782-8.
35. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991; 34:416-22.
36. Alexander CM, Landsman PB, Teutsch SM, Haffner SM; Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52:1210-4.
37. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110:1251-7.
38. Golden SH, Folsom AR, Coresh J, Sharrett AR, Szklo M, Brancati F. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. Diabetes 2002; 51:3069-76.
39. Wang J, Ruotsalainen S, Moilanen L, Lepistö P, Laakso M, Kuusisto J. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J 2007; 28:857-64.
40. Pladevall M, Singal B, Williams LK, Brotons C, Guyer H, Sadurni J, et al. A single factor underlies the metabolic syndrome. Diabetes Care 2006; 29:113-22.
41. Tang W, Pankow JS, Arnett DK. Re: (Mis)use of factor analysis in the study of insulin resistance syndrome. Am J Epidemiol 2005; 162:921-2.